Back to Search
Start Over
A pump-prime aprotinin dose in cardiac surgery: Appraisal of its effects on the hemostatic system
- Source :
- Journal of Cardiothoracic and Vascular Anesthesia. 11:835-839
- Publication Year :
- 1997
- Publisher :
- Elsevier BV, 1997.
-
Abstract
- Objectives: To examine pump-prime aprotinin action on coagulation and fibrinolysis in patients undergoing primary coronary revascularization. Design: A prospective randomized study. Setting: A university hospital. Participants: Forty-three patients were randomly assigned to either group A, 21 patients treated with 2 × 106 kallikrein inhibitor units (KIU) of aprotinin in the cardiopulmonary bypass (CPB) prime, or group B, 22 patients, untreated. Interventions: Patients, scheduled for elective coronary surgery, were treated with 2 × 106 KIU of aprotinin in the CPB prime. Markers of coagulation and fibrinolysis were evaluated. Measurements and Main Results: Surgical times, number of reopenings, and allogeneic blood requirements were collected for each patient. Blood samples were obtained before and after surgery for assessing coagulation (prothrombin time [PT], activated partial thromboplastin time [aPTT], ethanol test, factor VII, antithrombin III [AT III], thrombinantithrombin III complex [TAT], fragment 1.2 of prothrombin [F1.2]) and fibrinolysis (fibrin degradation products [FDP], plasmin-antiplasmin complexes [PAP], D-dimers) markers variations. In group A surgical times were faster, there were fewer reopenings (0 v 3), and fewer blood transfusions (1 patient v 4 patients). The two groups did not differ for PT, aPTT, and fibrinogen measurements. Postoperative FDP (measurable in more patients of group B at the end of the operation), PAP, and D-dimers postoperatory levels (less increased in aprotinin group) show the antifibrinolytic properties of the drug. Regarding the coagulation markers, factor VII decreased, whereas TAT and F1.2 increased, all to a lesser extent in the aprotinin group compared with the untreated patients, at the end of operation. Conclusion: Pump-prime aprotinin minimized, even if not completely inhibited, the activation of coagulation and fibrinolysis during CPB, possibly ensuring a less complicated and safer postoperative recovery. It seemed to allow the maintenance of a correct balance of hemostatic systems, avoiding the risk of thrombotic phenomena.
- Subjects :
- Adult
Male
Antifibrinolytic
medicine.drug_class
medicine.medical_treatment
Hemostatics
law.invention
Aprotinin
law
Fibrinolysis
medicine
Cardiopulmonary bypass
Humans
Prospective Studies
Blood Coagulation
Aged
Prothrombin time
Cardiopulmonary Bypass
medicine.diagnostic_test
business.industry
Antithrombin
Middle Aged
Anesthesiology and Pain Medicine
Coagulation
Anesthesia
Female
Cardiology and Cardiovascular Medicine
business
Partial thromboplastin time
medicine.drug
Subjects
Details
- ISSN :
- 10530770
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Journal of Cardiothoracic and Vascular Anesthesia
- Accession number :
- edsair.doi.dedup.....54612a13163c253114651230e4f689e3
- Full Text :
- https://doi.org/10.1016/s1053-0770(97)90116-6